/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Professor Colin Baigent FMedSci is Director of the MRC Population Health Research Unit and Deputy Director of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford, where he is Professor of Epidemiology. Professor Baigent’s main scientific interests are in the design and conduct of large-scale randomized trials and the use of meta-analysis to assess the efficacy and safety of drugs for treating or preventing cardiovascular disease. He has a particular interest in the epidemiology of CVD in renal failure, and led the Study of Heart and Renal Protection (SHARP), which showed that lowering LDL cholesterol significantly reduced the risk of atherosclerotic events in patients with chronic kidney disease. His group is now coordinating the EMPA KIDNEY trial of empagliflozin vs placebo in over 6,000 patients with CKD. He was co-chair of the 2019 ESC/EAS lipid guidelines and chair of the ESC Clinical Practice Guidelines Committee (2020-2).
